Full history for every metric is available with a Kvantra account
SQI Diagnostics Inc. (SQIDF)
Key financial summary
Financials in CAD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | 1 | 1 | 2 | 1 | 1 | 8 | 3 |
| Operating profit | CAD m | -20 | -17 | |||||
| Net profit | CAD m | -6 | -7 | -8 | -9 | -11 | -19 | -20 |
| EPS reported | CAD | -0.05 | -0.05 | |||||
| Operating cashflow per share | CAD | -0.03 | -0.03 | |||||
| Capex per share | CAD | 0.00 | 0.00 | |||||
| FCF per share | CAD | -0.03 | -0.03 | |||||
| Free cash flow | CAD m | -11 | -6 | |||||
| Net debt | CAD m | 13 | 15 | |||||
| Book value equity | CAD m | -10 | -15 | |||||
| Book value per share | CAD | -0.03 | -0.04 | |||||
| Number of shares | m | 389.72 | 406.25 | |||||
| DPS (TTM paid) | CAD | 0.00 | 0.00 |
Financial summary
Financials in CAD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -4.12 | -0.59 | |||||
| P/S LTM | x | 4.99 | 2.84 | |||||
| P/FCF LTM | x | -3.67 | -1.33 | |||||
| EV/EBITDA LTM | x | -5.51 | -2.05 | |||||
| EV/Sales LTM | x | 6.83 | 7.61 | |||||
| Earnings Yield LTM | % | -45.83% | -223.93% | |||||
| FCF Yield | % | -27.28% | -75.10% | |||||
| Quality | ||||||||
| ROE | % | 188.78% | 447.09% | |||||
| ROIC | % | -302.55% | -302.55% | |||||
| Operating margin | % | -241.42% | -241.42% | |||||
| Gross margin | % | 38.30% | 38.30% | |||||
| FCF/Sales | % | -136.09% | -136.09% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +783.53% | -50.11% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.68 | -0.43 | |||||
| Net Debt/EBITDA | x | -1.49 | -1.49 | |||||
| EBIT/Net interest | x | -7.52 | -7.52 | |||||
| Net debt/market cap | % | 31.08% | 167.88% | |||||
| Net debt/Equity | x | -1.28 | -1.00 | |||||
| Gross debt/equity | x | -1.66 | -1.04 | |||||
Company overview
SQI Diagnostics Inc. operates as a precision medicine firm, engaged in the global identification, advancement, and marketing of swift diagnostic solutions tailored for medical professionals, patients, and the general public. Its diverse product portfolio features TOR-dx, a specialized lung test designed to help surgeons evaluate the condition of donor lungs. The company also offers an at-home antibody test kit for COVID-19, along with RALI-Dx, a laboratory-based test for triaging COVID-19 severity, and RALI-fast, its rapid point-of-care alternative for the same purpose. Furthermore, SQI Diagnostics provides essential microarray instruments to support antibody testing procedures. The company was founded in 1999 and maintains its corporate headquarters in Toronto, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
SQI Diagnostics Inc. (SQIDF)
SQI Diagnostics Inc. operates as a precision medicine firm, engaged in the global identification, advancement, and marketing of swift diagnostic solutions tailored for medical professionals, patients, and the general public. Its diverse product portfolio features TOR-dx, a specialized lung test designed to help surgeons evaluate the condition of donor lungs. The company also offers an at-home antibody test kit for COVID-19, along with RALI-Dx, a laboratory-based test for triaging COVID-19 severity, and RALI-fast, its rapid point-of-care alternative for the same purpose. Furthermore, SQI Diagnostics provides essential microarray instruments to support antibody testing procedures. The company was founded in 1999 and maintains its corporate headquarters in Toronto, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free